Loading
institutionsInstitution
UZ Leuven / Leuven Cancer Institute
Belgium's largest university hospital and an OECI-accredited comprehensive cancer centre, with world-class gastrointestinal, gynaecological and angiogenesis research.
Also called: Leuvens KankerinstituutLKIUniversity Hospitals Leuven
Overview
The Leuven Cancer Institute coordinates cancer care and research across UZ Leuven and KU Leuven and holds OECI comprehensive cancer centre status. Eric Van Cutsem's gastrointestinal group led the CRYSTAL and other trials that defined anti-EGFR therapy in RAS wild-type colorectal cancer, Ignace Vergote shaped surgical and medical management of ovarian cancer through EORTC and ENGOT trials, and Frédéric Amant founded the international network on cancer during pregnancy. The VIB-KU Leuven Center for Cancer Biology (Peter Carmeliet, Diether Lambrechts, Jean-Christophe Marine) is a leading site for angiogenesis, tumour genomics and melanoma research, and Hans Wildiers is a reference in geriatric oncology. The ParTICLe proton therapy centre opened on the Gasthuisberg campus in 2020.
Location
Leuven, BE
Type
cancer center · KU Leuven
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#110 · 38 points (0 Newsweek + 0 NCI + 38 from 19 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Universitair Ziekenhuis Leuven, including child institutions. 343 works · 5,732 citations · 76% open access · 16% clinical trials · 2% reviews.
Oncology works per year
562022
862023
732024
722025
562026
Most works
- Eric Van Cutsem53 works
- Frédéric Amant28 works
- Josep Tabernero24 works
- Patrick Neven23 works
- Christine Desmedt22 works
- Takayuki Yoshino19 works
- Ines Nevelsteen18 works
- Giuseppe Floris18 works
- Hans Wildiers17 works
- Oliver Bechter16 works
Most cited
- Gastrointestinal oncology
- Gynaecological oncology
- VIB-KU Leuven Center for Cancer Biology
- ParTICLe proton therapy
- Geriatric oncology
Eric Van Cutsem
Professor of Medicine and Head of Digestive Oncology, University Hospitals Leuven
Colorectal cancerGastro-oesophageal cancerAnti-EGFR therapy
Led CRYSTAL, which established cetuximab in RAS wild-type colorectal cancer, and has shaped ESMO's GI guidelines for two decades.
Ignace Vergote
Emeritus Professor of Gynaecologic Oncology, University Hospitals Leuven; Chair, BGOG and ENGOT
Gynaecologic oncologyNeoadjuvant chemotherapyAntibody-drug conjugates
Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer.
Patrick Schöffski
Head of General Medical Oncology, UZ Leuven and Leuven Cancer Institute
Soft tissue sarcomaEarly-phase drug developmentRare cancers
Leuven oncologist who led the trial that showed eribulin lengthens survival in advanced liposarcoma, the basis of the drug's approval for that disease.
Paul Herijgers
Chief Executive Officer, UZ Leuven
Hospital leadershipAcademic medicineHealth system governance
Chief executive of the Leuven university hospital, whose Leuven Cancer Institute brings clinicians and scientists together to treat and study cancer.
Similar pages
- InstitutionCentre Antoine Lacassagne
Shares IBA (Ion Beam Applications), Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, Melanoma.
- TrialAVF2107g
Shares VEGF / VEGFR, Anti-angiogenic therapy, Monoclonal antibodies, Colorectal cancer.
- Key paperFruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)
Shares Eric Van Cutsem, VEGF / VEGFR, Anti-angiogenic therapy, Colorectal cancer.
- TrialRAISE
Shares VEGF / VEGFR, Anti-angiogenic therapy, Monoclonal antibodies, Colorectal cancer.
- TechnologyProton arc therapy
Shares IBA (Ion Beam Applications), Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy.
- TrialCALGB/SWOG 80405
Shares VEGF / VEGFR, Anti-angiogenic therapy, EGFR, Monoclonal antibodies.
- PersonFrank Vermassen
Shares Ghent University Hospital / Cancer Research Institute Ghent, Organisation of European Cancer Institutes.
- Key paperRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT)
Shares Eric Van Cutsem, VEGF / VEGFR, Anti-angiogenic therapy, Colorectal cancer.